10.6084/m9.figshare.4822927.v1
Dereure O.
Dereure
O.
Missan H.
Missan
H.
Girard C.
Girard
C.
Costes V.
Costes
V.
Guillot B.
Guillot
B.
Supplementary Material for: Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients
Karger Publishers
2017
Cutaneous squamous cell carcinoma
Locally advanced disease
Metastatic disease
Cetuximab
2017-04-06 09:17:21
Journal contribution
https://karger.figshare.com/articles/journal_contribution/Supplementary_Material_for_Efficacy_and_Tolerance_of_Cetuximab_Alone_or_Combined_with_Chemotherapy_in_Locally_Advanced_or_Metastatic_Cutaneous_Squamous_Cell_Carcinoma_An_Open_Study_of_14_Patients/4822927
<p><b><i>Background/Aims:</i></b> Previous reports highlighted the
potential interest of cetuximab alone or in combination with
chemotherapy in locally advanced or metastatic cutaneous squamous cell
carcinomas (cSCC) care. <b><i>Material and Methods:</i></b> To further
evaluate the efficiency and safety of cetuximab in advanced cSCC, a
single-center retrospective study including all patients treated with
cetuximab alone or combined with carboplatin for locally advanced or
metastatic cSCC was conducted in a tertiary referral center. The primary
end point was the overall response rate (ORR) after 2 cycles of
treatment. Secondary end points were best overall disease control rate
(DCR), overall survival (OS), best response duration, progression-free
survival (PFS), and toxicity profile. <b><i>Results:</i></b> Of the 14
enrolled patients, no complete response was obtained after 2 cycles of
treatment, but 3 partial responses and 6 stable diseases were observed.
ORR and DCR were 21.4 and 64.3%, respectively. Median OS and PFS were
9.25 and 2.65 months, respectively. Median PFS was longer with combined
treatment compared with cetuximab monotherapy (9.03 vs. 3.55 months).
The safety profile was acceptable with a trend toward a relationship
between acne-like rash and longer response (median PFS 5.2 vs. 2.2
months). <b><i>Discussion/Conclusion:</i></b> In all series including
ours, disease control is usually rapidly obtained with cetuximab alone
or combined with conventional chemotherapy, although with a minority of
partial responses and no complete response. However, this control is of
short duration in most cases. The safety profile is acceptable. A
randomized phase III trial is warranted to better assess the
benefit/risk ratio.</p>